drugset / Trial / NCT04537286
First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin plus carilizumab as first-line treatment in patients with metastatic triple-negative breast cancer.
Timeline
- Start
- 2020-08-25
- Primary completion
- 2024-09-15
- Completion
- 2024-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |